TORL-1-23 is a novel antibody-drug conjugate (ADC) that targets the tumor-associated protein Claudin 6 (CLDN6), which is overexpressed in several types of cancer, including ovarian, endometrial, and testicular cancer [118]. The gene discussed is CLDN6; the disease is testicular cancer.